ReviewOncology letters2026
Metabolic heterogeneity and functional diversity of cancer-associated fibroblasts in gastric cancer (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a major global health challenge characterized by poor prognosis and high mortality rates, despite advances in anticancer therapies. Increasing evidence indicates that GC is a highly stromal-rich tumor, with cancer-associated fibroblasts (CAFs) serving as key stromal components of the tumor microenvironment (TME). CAFs exhibit substantial metabolic heterogeneity, such that distinct CAF subtypes demonstrate intrinsic differences and dynamic remodeling in glucose, lipid and amino acid metabolism. This metabolic reprogramming represents not only functional diversity but also an adaptive response to microenvironmental stressors, including tumor-derived signals, hypoxia, nutrient fluctuations and oxidative stress. Through these adaptations, CAFs engage in extensive crosstalk with tumor and immune cells, thereby contributing to microenvironmental remodeling. Due to their critical role and abundance in GC, CAFs have emerged as promising therapeutic targets. The present review summarizes the origins, characteristics and heterogeneity of CAFs in GC and discusses their interactions with the TME. In addition, it summarizes the metabolic heterogeneity of CAFs, explores potential metabolism-targeted therapeutic strategies and outlines the broader impact of CAFs on the TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.